(CCR2015) Nearly 100 new molecules are in development as RA treatments. This summary of a recent presentation by the ever-eloquent Ed Keystone MD gives a brief rundown of their mechanisms, progress, and potential.
Are you letting meaningless details squander your mental currency in rheumatology practice? The author points out how to recapture energy stolen by mere paperwork that should be used on your real job: Patient care.
Several new studies feature developments in remyelination in MS. Oligodendrocyte precursor cells may be a promising target for MS treatments, and microRNA expression are perhaps an attractive MS biomarker.